In this interview, the expert of industry Dr. Lohit Khera discusses Microrna’s evolving role in research, diagnosis and precision medicine. It also highlights the latest RNA and resolution innovations and how these advanced technologies face key challenges in small RNA research.
What initially aroused scientific interest in Microorn and how did this focus evolve over the last decade?
The discovery that microornas (mirnas) regulate gene expression after transcription was a shift in the example and their role in developmental biology and cancer has diverted the attention of researchers worldwide.
In the last decade, the field exploded with the discovery of biomarkers from liquid biopsy samples, diagnostics and even therapeutic, where researchers design mimicry and mirna inhibitors. It becomes a translation science, with strong branches and clinical ties.
What does microrna make such a strong target in current biological and biomedical research?
Micrors have a rare leverage because they act as molecular switches that perfect whole gene networks. May or may not be specifically for individual genes. They are also firmly in biochets, making the ideal candidates for non -invasive diagnostics of liquid biopsy samples. Tissue and disease expression standards provide specialization and the optimized Mirna extraction kits bring ease of use and sensitivity, which is exactly what researchers want in their biomarkers or therapeutic goals.
Why is the ability to isolate all RNA sizes – especially micrors – so vital to researchers today?
Small rnas are strangely difficult to capture with traditional kits that favor larger transfers, but their functional significance is enormous. Many laboratories may lose critical data because their export methods are not optimized for the “actual” total RNA recovery. Whether it is a targeted microrna expression profile or sequence determination, you need high quality microenison at appropriate concentrations. This ensures reproducibility and accuracy, especially when working with low input such as biofthoid or degraded samples such as FFPE tissue.
What are the biggest challenges facing researchers when working with small RNA and how are these emerging technologies treated?
Low abundance and infectious background noise are persistent obstacles. Small RNAs are often lost during the extraction due to low abundance and common extraction technologies suffering from intrinsic prejudice to large nuclein acids. Although the best binding chemicals and extremely low input kit promises better extraction, they must depend either on the use of a large RNA carrier or on powerful chemicals that can eventually reach the final RNA output and interfere with downward applications. Silicon carbide is a revolutionary resin that can capture a small RNA without the need for RNA carrier or unwanted chemicals.
Background noise is another dominant issue that is more concerned with NGS -based applications. This noise of the background uses critical reagents during small RNA sequence and affects the readings that have been mapped by genome and mirna mapping. Norgen has recently released the Extraclean Kit, which eliminates this issue, significantly enhancing the production of small RNA sequences.
You can share the story behind the founding of Norgen Biotek Corp. and the problem originally set to solve the RNA survey?
Norgen Biotek Founded by Dr. Yosef Haj-Ahmad, a scientist with a mission to develop and manufacture revolutionary nucleic acid (NA) cleansing kits, especially from complex samples such as the serum or FFPE tissue. The main issue was the performance and integrity for small NAS such as exosomal RNA and DNA without cells (CFDNA). We wanted to develop a platform that delivered consistent, high quality small RNA to all fragments up to 20-25-nucleotide mirnas. The technology based on silicones based on this need was born of this need. It is now used by researchers who do not have the luxury of losing a signal due to partial recovery.
Credit Picture: Norgen Biotek Corp.
Norgen has developed the unique technology based on silicon carbide for RNA isolation. How does this approach compare to more traditional silicon -based methods?
The silicon carbide has a wider commitment profile than silicon dioxide, especially for low molecular weight nucleic acids. This means that we can maintain long and small RNA and RNA with low and high GC content. Traditional silicon dioxide columns tend to favor transcriptions of larger and high GCs and can undermine microornas or fragmented rnas. Our approach offers better consistency, especially for complex or low input samples.
Credit Picture: Norgen Biotek Corp.
What are some of the most promising Microorn applications in areas such as oncology, agriculture or diagnostics?
In oncology, circulating micrors convert the way we detect and monitor cancers. They offer real -time snapshots of volume load and treatment response.
In agriculture, plants are explored to improve crop resistance and resistance of diseases. Diagnostic applications such as salivary micrena for oral cancer or urinary tract microna for kidney disease.
How is micrors used to promote innovation in non -invasive or minimally invasive diagnostics?
Micrors are ideal for wet biopsies – they can be isolated from plasma (blood), urine and saliva and their expression patterns change with the condition of the disease. This makes them ideal for early detection and monitoring without the need for tissue biopsies. We see diagnostic panels occurring for cancer, cardiovascular conditions and even neurodegenerative diseases. Some companies even combine microrna profiles with mechanical learning to enhance the prediction. It is a jump to the affordable, non -invasive diagnostic that can be used in the usual sorting.
As demand increases for precision medicine, how do you see RNA – especially small RNA – that has the future of personalized treatment?
Small rnas become the molecular fingerprints of the disease. Their ability to reflect their dynamic physiological situations make it incredibly useful in adapting treatments. For example, Microorn signatures can help pervert patients and predict therapeutic response to cancer. As we incorporate the multi-OMICS into precision medicine, the microrna profile offers a complementary layer that bridges gene expression with a clinical phenotype. I think in the near future, we will see more and more inclusion of therapeutic decisions that have been informed by smallly informed.
The last two Nobel Prizes in Physiology have highlighted RNA-based discoveries-what does this say about the future of this field?
It highlights the central role of RNA in biology and medicine. From the identification of Mirna many years ago to the recent impact of the modified MRNA for the COVID-19 vaccine, the nobles reflect decades of fundamental work that ultimately bear fruit. This ratification contributes to the increase in funding, innovation and public interest. RNA is no longer only a messenger, it is a tool, a therapeutic and a diagnostic molecule. The future of biomedical will have RNA in the center.
How do you envision the role of automation and AI in the future of RNA extraction and analysis?
Automation is the key to consistency, especially as laboratories increase test or function in adjustable environments. We see more demand for prepared automation kits and gradual protocols for a variety of volumes of liquid biopsy samples. Meanwhile, AI transforms the interpretation of data from Microorn -based diagnostics, where expression patterns can be thin. Mechanical learning algorithms can detect clinically related standards that include many different mirnas that are easy to lose with traditional methods. Together, the automation and discovery of AI acceleration, while minimizing the human error, making RNA work flows more effective and reproducible.
About Dr. Lohit Khera 
Dr. Khera is the head of scientific sales at Norgen Biotek. With more than 10 years of experience in research on cancer and molecular biology from recognized institutions such as the Institute of Science and the LSU Health Science Center, Dr. Khera is dedicated to promoting global research and diagnostic cancer through cutting -edge technologies.
